These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 27544566)
1. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer. Wang Y; Dason S; Shayegan B Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Han CS; Patel R; Kim IY Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418 [TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302 [TBL] [Abstract][Full Text] [Related]
5. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. Scott LJ Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727 [TBL] [Abstract][Full Text] [Related]
6. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. Svensson J; Andersson E; Persson U; Edekling T; Ovanfors A; Ahlgren G Scand J Urol; 2016 Aug; 50(4):286-91. PubMed ID: 27109827 [TBL] [Abstract][Full Text] [Related]
7. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676 [TBL] [Abstract][Full Text] [Related]
9. Germline Variant in Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
11. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222 [TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
13. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562 [TBL] [Abstract][Full Text] [Related]
14. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919 [TBL] [Abstract][Full Text] [Related]
15. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999 [TBL] [Abstract][Full Text] [Related]
16. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155 [TBL] [Abstract][Full Text] [Related]
17. A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Thortzen A; Thim S; Røder MA; Brasso K Urol Oncol; 2016 Jul; 34(7):291.e1-7. PubMed ID: 26971191 [TBL] [Abstract][Full Text] [Related]
18. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
19. Abiraterone acetate in the treatment of prostate cancer. Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958 [TBL] [Abstract][Full Text] [Related]
20. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]